Preliminary Remarks Concerning Cytology
The data presented here are based on blood and bone marrow studies performed on a series of patients, most of whom were diagnosed and followed up by SPRANGER (Mainz). Other valuable preparations were contributed by DI FERRANTE (Houston), MAROTEAUX (Paris), MAUMENEE and MCKUSICK (Baltimore), OPITZ (Madison), RAMPINI (Zürich), WIEDEMANN (Kiel), and others (see page 71). Only through this successful international cooperation, reinforced by an international therapy program and cytological follow-ups, was it possible to obtain a comparatively large amount of material (Table 4). With such rare diseases, it is not surprising that a few omissions remain. In addition, we had preparations from patients apparently suffering from exceedingly rare and as yet unidentified diseases (see “other forms”). Those patients whose cytological findings cannot be clearly associated with any of the defined diseases are included in the group “unclassified.”
KeywordsEDTA Leukemia Citrate Assure Toluidine
Unable to display preview. Download preview PDF.